Concerns about an increased hepatocellular carcinoma (HCC) recurrence rate following direct-acting antiviral (DAA) therapy in patients with cirrhosis with a prior complete oncological response have been raised. Data regarding the impact of HCV treatment with DAAs on wait-list dropout rates in patients with active HCC and HCV-related cirrhosis awaiting liver transplantation (LT) are lacking. HCV-HCC patients listed for LT between January 2015 and May 2016 at Padua Liver Transplant Center were considered eligible for the study. After enrollment, patients were divided into 2 groups, depending on whether they underwent DAA treatment while awaiting LT or not. For each patient clinical, serological, and virological data were collected. HCC characteristics were radiologically evaluated at baseline and during follow-up (FU). For transplanted patients, pathological assessment of the explants was performed and recurrence rates were calculated. A total of 23 patients treated with DAAs and 23 controls were enrolled. HCC characteristics at time of LT listing were comparable between the 2 groups. Median FU was 10 and 7 months, respectively, during which 2/23 (8.7%) and 1/23 (4.3%) dropout events due to HCC progression were registered (P 5 0.90). No significant differences in terms of radiological progression were highlighted (P 5 0.16). A total of 9 out of 23 (39%) patients and 14 out of 23 (61%) controls underwent LT, and histopathological analysis showed no differences in terms of median number and total tumor volume of HCC nodules, tumor differentiation, or microvascular invasion. During post-LT FU, 1/8 (12.5%) DAAtreated patient and 1/12 (8.3%) control patient experienced HCC recurrence (P 5 0.60). In conclusion, viral eradication does not seem to be associated with an increased risk of dropout due to neoplastic progression in HCV-HCC patients awaiting LT. 
worldwide. (1) Patients with cirrhosis experience a very high risk of hepatocellular carcinoma (HCC) development with a 5-year cumulative incidence of up to 30%, with the highest risk among those infected with HCV (2) as a result of the chronic inflammation associated with viral replication. This is corroborated by the fact that among HCV-infected patients with cirrhosis, HCC has been the main indication for listing. (3) The new era of direct-acting antiviral (DAA) agents has already changed the management approach to HCV infection in the transplant setting. (4, 5) It is anticipated that the widespread application of DAA therapy in the near future could lead to a significant reduction in HCV-related end-stage liver disease and HCC, (6) and the number of patients listed for LT will decrease markedly. (7) However, DAA treatment rates are limited by the high cost in resource-limited environments and patients with HCV infection are not universally linked to care. (8) It is therefore likely that HCV-related cirrhosis will continue to be a significant indication for LT in the coming decades. (9) Unlike the previous interferon (IFN)-based treatments, (10, 11) most DAAs can be considered highly safe and well-tolerated, even in patients with advanced liver disease. (12) (13) (14) However, it is in this population that concerns about a high recurrence rate of HCC have been raised in patients who previously had a complete response to locoregional HCC treatment and were subsequently treated with DAAs. (15) After the first report by Reig et al., several further studies have been published, exploring the potential role of DAA-based treatment in HCC occurrence and recurrence processes. (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) To our knowledge, the impact of HCV eradication by DAAs on the progression of HCC in patients with active neoplastic disease has not been fully evaluated.
Belli et al. have shown that, through successful DAA treatment, "delisting" is possible in almost one-third of patients with nononcological indications, reducing the need for LT in HCV-positive patients and allowing organs to be allocated to others. (26, 27) However, dropout from the waiting list, due to tumor progression and the development of oncological contraindications to LT, represents a major challenge in the management of patients with HCC. (28) Therefore, if it were shown that HCV eradication by DAAs is related to the induction of HCC growth and progression in patients with active neoplastic disease, there would be major consequences in relation to the timing of DAA therapy.
The aim of this study was therefore to investigate whether patients listed for HCC and treated with DAAs have an increased rate of tumor progression and consequent dropout from the waiting list for LT at Padua Liver Transplant Center.
Patients and Methods

PATIENTS
We retrospectively evaluated all consecutive patients listed for LT at Padua Liver Transplant Center between January 2015 and May 2016. Patients, whose indication for LT was HCC with HCV-related cirrhosis and detectable viremia at time of listing for LT, were included in the study. They were subsequently divided into 2 groups, depending on whether they underwent DAA treatment while awaiting LT or not. Eligibility for DAA treatment was assessed following the criteria established by the national registry of the Italian Medicines Agency Committee. At that time, there was not a single-center protocol regarding the management of antiviral therapy in patients awaiting liver transplant. Thus, the decision to start antiviral treatment before LT was at the discretion of the different hepatologists, and it was mainly based on the probability of being transplanted (in patients with a high probability of getting liver transplanted in a short while, antiviral therapy was postponed after the transplant).
Exclusion criteria were as follows: age < 18 years, patients listed for other coetiologies in addition to HCV-related cirrhosis, hepatitis B virus coinfections, and retransplantations. The inclusion criteria flow chart is shown in Fig. 1 .
Demographic, clinical, and virological data were collected. Virological response to treatment was assessed by quantitative HCV RNA detection, using real-time PCR with a limit of detection of 12 IU/mL. The study was approved by the Padua University Hospital ethical committee.
HEPATOCELLULAR CARCINOMA
Diagnosis of HCC was based on the European Association for the Study of Liver guidelines. (29) As previously published, our policy for listing is based on the exclusion of HCC with aggressive features such as poor differentiation (G3 according to Edmondson's score), presence of vascular invasion and/or extrahepatic spread, alpha-fetoprotein (AFP) levels higher than 400 ng/mL, and irreversible radiological progression after downstaging treatments. On the other hand, size and number of nodules are not considered as absolute selection criteria. (30) (31) (32) At time of listing for LT and at the end of follow-up (FU), morphological HCC characteristics were collected through computed tomography (CT) scan or magnetic resonance imaging (MRI) that were performed quarterly according to routine FU schedules. Radiological progression was defined according to modified Response Evaluation Criteria in Solid Tumors criteria. (33) Vital tumor volume was quantified according to the following equation: Tumor volume in cm 3 5 4/3 3 3.14 3 (radius of the tumor nodule in cm 3 ). Total tumor volume (TTV) was calculated as the sum of the tumor volume of each nodule. (34, 35) The radiological response was assessed by 1 expert radiologist who was unaware of both the clinical and DAA treatments.
Downstaging treatments on the waiting list (radiofrequency or microwave ablation, liver resection, and transarterial chemoembolization) performed according to Padua Liver Transplant Center policy (30) were recorded.
FU AND DROPOUT
The FU period was defined as the total time spent on the LT waiting list, beginning at listing time and stopping at transplantation or, alternatively, at dropout due to tumor progression or death on the waiting list. For patients who did not reach the established end of FU (ie, patients still awaiting LT at the end of the study period), we collected the most recent data available. In our center, during wait-list permanence, all HCC patients are treated with an aggressive multimodal adjuvant protocol to contain tumor progression prior to LT. (36) (37) (38) (39) During the FU, bridge treatments (radiofrequency or microwave ablation, liver resection, and transarterial chemoembolization) were recorded. Vital tumor active burden was re-evaluated through the above-mentioned radiological techniques 1 month after each bridge treatment, according to clinical practice guidelines. (29) Patients were excluded from the LT waiting list during FU if there was evidence of the following: neoplastic vascular macroinvasion, extrahepatic metastases, AFP levels rising over 400 ng/mL, irreversible radiological progression after bridging treatment, or poor tumor differentiation if a tumor biopsy was performed (G3 HCC). (30) (31) (32) 40, 41) Patients were also followed up after LT for HCC recurrence, through CT scan or MRI, every 3 months during the first year and every 6 months thereafter, according to European Association for the Study of the Liver/European Organization for Research and Treatment of Cancer clinical practice guidelines. (29) The post-LT HCC recurrence rate was calculated using the most recent radiological data available at the end of the study.
OBJECTIVES
The primary objective was the rate of exclusion from the LT waiting list, due to neoplastic progression in both cohorts; secondary objectives were rates of radiological progression and transplantation, histopathological HCC characteristics, and the post-LT HCC recurrence rate.
For transplanted patients, explant pathology evaluation was performed (number and TTV of HCC nodules, tumor differentiation, and presence of microvascular invasion) by 1 expert pathologist who was unaware of DAA treatments.
STATISTICAL ANALYSIS
Qualitative data were described by frequency and percentage. Quantitative data were described by median (range). In the comparison between different subgroups, quantitative variables were compared using Student t or Wilcoxon rank sum tests, as appropriate. Categorical variables were compared using v 2 or Fisher's exact tests, as appropriate.
Median waiting time on the waiting list was expressed as median (range). Dropout and LT probabilities were calculated from the day of wait-list inclusion until dropout from any cause during the waiting list, LT, or latest FU. Dropout was defined as removal from the waiting list due to disease progression or patient death before LT. To construct and compare dropout and LT probability curves in the study and control groups, we used the competing risk method described by Fine and Gray. (42) This method allows for all patients to be placed into a category: transplanted, dropped-out, or still waiting.
In all analyses, a 2-tailed P value < 0.05 was considered statistically significant. All analyses were performed using the JMP 9.0.1 package (SAS Institute Inc., Cary, NC), and R.app GUI 1.51 (R Foundation for Statistical Computing, Vienna, Austria).
Results
PATIENTS
Out of 244 patients listed for LT at Padua Liver Transplant Center, 198 did not meet the inclusion criteria (13 were under-age, 11 were listed for retransplantation, 141 either for non-HCV-related cirrhosis or had a previous virological response, and 33 had HCV-related cirrhosis with no evidence of HCC). Forty-six patients with HCC and HCV-related cirrhosis with detectable viremia at time of listing for LT were included in the study.
Twenty-three of them underwent antiviral treatment with DAAs during the FU. Treatment regimens were as follows: 13 patients were treated with the association of ledipasvir (LDV) and sofosbuvir (SOF; 57%), 4 with daclatasvir (DCV) and SOF (17%), 3 with simeprevir and SOF (13%), and 3 with SOF alone (13%), for most patients the antiviral treatment was held for 12 weeks, starting within 1 month since listing time. Ribavirin (RBV) was added to the treatment schedule in 13 (57%) patients. All treated patients achieved sustained viral response (SVR; 23/ 23, 100%).
A second group of 23 patients with cirrhosis remained untreated while listed and thus maintained detectable viremia for the entire FU. Age, sex, and virological characteristics were comparable in the 2 groups.
Compared with the controls, the median Model for End-Stage Liver Disease (MELD) score for DAAtreated patients was lower (median, 10 versus 11; range, 7-17 versus 6-28, respectively; P 5 0.09) as was the percentage of more advanced patients according to the Child-Turcotte-Pugh (CTP) score (A/B/C: 15/8/ 0 versus 13/3/7; P 5 0.09); however, these differences were not statistically significant. Table 1 shows the patients' baseline characteristics, and Table 2 shows the reasons for not treating patients in the control group.
HEPATOCELLULAR CARCINOMA
At baseline, the 2 groups were comparable in terms of the median number of HCC nodules (median, 2 versus 2; range, 1-4 versus 1-6, respectively; P 5 0.83), TTV (median, 96 versus 92 cm 3 ; range, 42-272 versus 34-222 cm 3 , respectively; P 5 0.97), and AFP levels (median, 6 versus 12 ng/mL; range, 2-300 versus 2-238 ng/mL, respectively; P 5 0.68) in the DAA and control groups, respectively. Both groups of patients underwent downstaging treatments before being listed (87% of treated patients and 96% of controls; P 5 0.90).
FU AND DROPOUT
Median FU was similar for the 2 groups (median, 10 versus 7 months; range, 6-19 versus 5-19 months; P 5 0.42), during which both groups of patients underwent bridge treatments (61% of treated patients and 26% of controls; P 5 0.003).
Comparing radiological images at the beginning and at end of FU, no significant differences in terms of radiological progression were highlighted, even though there was a positive trend in the treated patients group; 35% of treated patients had radiological progression versus 17% of controls (P 5 0.16; Fig. 2 ). Furthermore, this slight positive trend was not supported by a parallel rise of AFP levels (AFP slope > 15 ng/mL/month in 2 patients among controls versus 0 DAA-treated patients; P 5 0.20).
During the FU, we registered 3 dropouts in the treated patients group (13%), due to patient death for intracerebral hemorrhage in 1 patient, and HCC progression in the other 2 patients (neoplastic portal vein thrombosis in 1 and subcutaneous metastases evidence in the other), and 3 dropouts in the control group (13%) due to patient deaths for sepsis-related multiorgan failure in 2 patients, and HCC nodule's number and size progression after bridge treatment in the other case.
In terms of comparison between crude frequencies, we did not find significant differences in the dropout rate due to HCC progression between groups (P 5 0.90), even when we considered all radiological progressions as potential dropouts (P 5 0.80).
The characteristics of patients excluded from the LT waiting list due to HCC progression are summarized in Table 3 . Competing risk curves showed no significant differences in terms of dropout probabilities between groups ( Fig. 3 ; P 5 0.80). Conversely, we found a significantly lower probability to be transplanted in treated patients when compared with controls (P 5 0.04).
Three patients died for nonneoplastic-related causes during the FU period. One patient belonged to the DAA-treated group and died from intracerebral hemorrhage, and 2 controls died both from multiorgan failure due to sepsis.
TRANSPLANTED PATIENTS
Histopathological Analysis
A total of 9 out of 23 (39%) patients treated with DAAs and 14 out of 23 (61%) controls underwent LT. Histopathological analysis of HCC performed on the explanted liver showed no differences in terms of the following: number (median, 3 versus 3; range, 1-7 versus 1-8; P 5 0.50); TTV of HCC nodules (median, 14.2 versus 11 cm 3 ; range, 5.4-78.5 versus 6.3-39.8 cm 3 ; P 5 0.3); tumor differentiation (G3 HCC %, 12.5% versus 14.3%; P 5 0.70); or microvascular invasion (cases %, 44% versus 29%; P 5 0.40).
Post-LT HCC Recurrence
Median (range) post-LT FU was 9 (6-13) months and 11 (3-18) months for DAA-treated patients and controls, respectively. During post-LT FU, 1/8 DAA-treated patient (12.5%) and 1/12 control (8.3%) experienced HCC recurrence (P 5 0.60), respectively, at 7 and 12 months after LT (characteristics showed in Table 4 ); 1 DAAtreated patient and 2 controls died soon after LT, and it was not possible to evaluate the post-LT outcome. A total of 10 out of 12 controls started antiviral treatment with DAAs within 2 months after LT, 6 of whom reached SVR at 12 weeks, 3 are still in treatment, and 1 is currently being evaluated for re-treatment after viral breakthrough.
Discussion
The recent approval of highly effective, well-tolerated DAA regimens has revolutionized the management of HCV-infected patients. (4, 5, 27) Nevertheless, some concerns, that wait to be more clearly evaluated, have been raised (8, 9, 15) and require further evaluation. One such concern is whether HCV clearance from the liver, together with the consequent impairment of the liver immunological microenvironment, can impact HCC biology. (15, 18, 20) Currently, there are no data regarding the role that antiviral therapy with DAAs might play in terms of tumor progression and consequent dropout from the waiting list, in patients awaiting LT for HCV-related cirrhosis and HCC.
Because HCV-HCC patients represent an important proportion of patients on LT waiting lists, it is crucial to understand any drug's hypothetical effect on oncological progression leading to exclusion or dropout from the waiting list. In our opinion, this subpopulation of patients with cirrhosis is an ideal model to answer the question of whether there is a contribution of DAA treatment to neoplastic progression because these patients have active cancer and are regularly studied on a quarterly basis with second-level radiological techniques. These features allow us to investigate if there is any additional effect of DAA therapy on HCC progression in a short FU period. Indeed, unlike patients with cirrhosis who are screened for HCC occurrence or recurrence after curative treatments, for whom neoplastic progression timings are less easily identifiable, in our cohort the neoplastic process was already underway and was well defined at the start of DAA treatment.
In our study, the 2 groups did not show any significant difference in terms of dropout rate, during a median FU of 10 and 7 months, this being our primary objective. Nevertheless, the small sample size as well as the 
ZANETTO ET AL. LIVER TRANSPLANTATION, September 2017
potential bias due to the retrospective nature of the study does not allow us to draw any definitive conclusions. There was a slight positive trend in the DAAtreated patients for radiological tumor progression, which was not statistically significant, and there was no concomitant AFP slope.
Interestingly enough, a significantly lower probability to be transplanted in treated patients when compared with controls was found. In this scenario, DAAbased antiviral therapy could be associated with an improvement of liver function, reducing the need of transplantation, as shown by Belli et al. (26) However, again, the small sample size does not allow us to draw any definitive assumptions.
During the FU period, a higher percentage of DAA-treated groups underwent bridge treatments compared with controls. This finding can be explained by the higher prevalence of patients with more advanced liver disease in the control group (even not statistically significant), which limited the feasibility of HCC locoregional treatments. We believe this could conceivably explain the same dropout rate even in the presence of a slightly higher radiological progression.
Nearly a third of the newly detected liver cancers in the study by Reig et al. (15) occurred in the first months after the start of antiviral therapy, suggesting that the time frame of most interest is during treatment and immediately afterward. Therefore, even though our FU is relatively short, it seems possible that HCV eradication by DAAs did not enhance HCC progression in our cohort, an effect that could be expected to be more rapid and more evident in patients with active tumors at the start of therapy.
Even though LT is considered a curative treatment for HCC, its recurrence is still possible, mostly in the period immediately after LT, so that radiological surveillance is mandatory. (29) In deciding whether to treat HCV patients with DAAs before or after LT, one must also take into account the potential role of DAAs in post-LT HCC recurrence. The French prospective multicenter study (22) Cohort) in which HCC recurrence was observed in 7/ 314 patients (2.2%). This recurrence rate appears to be lower in these post-LT DAA recipients compared with that expected, which ranges from 8% to 20% within the first 2 years after LT. (43) Conversely, Yang et al. found in their study a trend toward a higher risk of HCC recurrence in patients who received pre-LT DAAs (5/18, 27.8%) compared with the risk in untreated patients (6/63, 9.5%; P 5 0.60). Interestingly enough, in patients who underwent DAA therapy a higher proportion of microvascular invasion in comparison to untreated controls was described (39% versus 28%; P 5 0.40), (24) similarly to what was found in our cohort (44% versus 29%; P 5 0.40).
In our cohort, we found similar post-LT HCC recurrence rates in the 2 groups (12.5% versus 8.3%; P 5 0.60), suggesting that there is no higher risk of tumor recurrence in patients treated with DAAs in the pre-LT treatment setting compared with post-LT treatment. Furthermore, we reported similar HCC patterns on liver explant histopathological analysis.
This study has some critical limitations. As previously reported, the most important one is certainly the small number of patients included. As a matter of fact, the number of HCC patients with radiological progression and microvascular invasion in the explant was higher among treated patients. Indeed, it is also possible that the difference was not statistically significant due to the low number of patients in each group. Furthermore, the small sample size may mean that the study was underpowered to detect a true difference in our primary objective and tumor progression.
Certainly, these should be considered as preliminary findings. Indeed, they must be confirmed in a different setting before considering the antiviral treatment with DAAs completely safe when offered in this patient population. Moreover, wait-list dropout rates depend on HCC management and wait-list inclusion/ exclusion criteria, that vary across centers, and these would need to be harmonized in a larger study.
Second, a longer FU (both before and after LT) would better reveal differences in terms of HCC progression and post-LT recurrence, respectively. Finally and importantly, the HCC tumor biology in our cohort might be unique in some way, but we are unable to describe this because we did not perform pre-LT HCC biopsies. Nevertheless, for patients who underwent LT during the study period, HCC histopathological analysis performed on explanted livers showed no differences in terms of tumor biology between pre-LT DAA-treated and control groups.
In conclusion, viral eradication with DAAs does not seem to be associated with an increased risk of dropout due to HCC progression in HCV patients awaiting LT even if, given the low number of patients included, prudence is clearly advised. The clinical implications of these findings deserve further and larger investigations. Additionally, it is true that the retrospective nature of the present study is not the appropriate way to define a firm causality between DAA treatment and HCC dropout or recurrence after transplant. Despite the important limitations mentioned above, to our knowledge this is the only study evaluating this very relevant and novel clinical question.
Deferring HCV treatment until after LT in order to guarantee access to the expanded pool of HCV-positive donors has been proposed as the most cost-effective strategy for well-compensated HCV-infected patients with cirrhosis listed for LT with HCC. (44) However, this still depends on HCV epidemiology. Furthermore, HCV eradication in the pre-LT setting prevents recurrence of liver infection (45) and has been associated with higher survival in patients transplanted for HCC. (46) Additionally, Martini et al. recently showed that reaching HCV RNA undetectability in the pre-or peri-LT setting could lower the risk of early allograft dysfunction in HCV-positive recipients. (47) This finding, together with our results, should further encourage clinicians to treat HCV patients as early as possible, especially in HCC patients awaiting LT who may be more likely to receive grafts from marginal donors with the consequent higher risk of post-LT complications. 
